SLC67A1 and central nervous system cancer: Consistently, Chu and coworkers showed that down-regulation of SLC22A18 was frequently associated with glioma development and that ectopic expression of SLC22A18 led to reduced proliferation of U251 glioma cells in vitro and in vivo [15].